[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK0602454T3 - N-oxycarbonylsubstituerede 5-deoxy-5-fluorcytidiner - Google Patents

N-oxycarbonylsubstituerede 5-deoxy-5-fluorcytidiner

Info

Publication number
DK0602454T3
DK0602454T3 DK93119349.4T DK93119349T DK0602454T3 DK 0602454 T3 DK0602454 T3 DK 0602454T3 DK 93119349 T DK93119349 T DK 93119349T DK 0602454 T3 DK0602454 T3 DK 0602454T3
Authority
DK
Denmark
Prior art keywords
radical
formula
deoxy
integer
protecting groups
Prior art date
Application number
DK93119349.4T
Other languages
Danish (da)
English (en)
Inventor
Nobuo Shimma
Motohiro Arasaki
Hideo Ishitsuka
Isami Kuruma
Masanori Miwa
Chikako Murasaki
Isao Umeda
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8210304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0602454(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK0602454T3 publication Critical patent/DK0602454T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
DK93119349.4T 1992-12-18 1993-12-01 N-oxycarbonylsubstituerede 5-deoxy-5-fluorcytidiner DK0602454T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP92121538 1992-12-18

Publications (1)

Publication Number Publication Date
DK0602454T3 true DK0602454T3 (da) 1996-07-29

Family

ID=8210304

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93119349.4T DK0602454T3 (da) 1992-12-18 1993-12-01 N-oxycarbonylsubstituerede 5-deoxy-5-fluorcytidiner

Country Status (41)

Country Link
US (1) US5472949A (fr)
EP (1) EP0602454B1 (fr)
JP (1) JP2501297B2 (fr)
KR (1) KR100347218B1 (fr)
CN (1) CN1035617C (fr)
AT (1) ATE137244T1 (fr)
AU (1) AU671491B2 (fr)
BG (1) BG61485B1 (fr)
BR (1) BR9305089A (fr)
CA (1) CA2103324C (fr)
CZ (1) CZ284788B6 (fr)
DE (1) DE69302360T2 (fr)
DK (1) DK0602454T3 (fr)
EE (1) EE03086B1 (fr)
ES (1) ES2086856T3 (fr)
FI (1) FI112365B (fr)
GE (1) GEP20074251B (fr)
GR (1) GR3020286T3 (fr)
HK (1) HK1005875A1 (fr)
HR (1) HRP931430B1 (fr)
HU (2) HU218291B (fr)
IL (1) IL108000A0 (fr)
IS (1) IS4108A (fr)
LT (1) LT3115B (fr)
LV (1) LV10625B (fr)
MY (1) MY109282A (fr)
NO (1) NO300066B1 (fr)
NZ (1) NZ250414A (fr)
PH (1) PH30168A (fr)
PL (1) PL174100B1 (fr)
RO (1) RO112619B1 (fr)
RU (2) RU2458932C2 (fr)
SA (1) SA93140409B1 (fr)
SI (1) SI9300648B (fr)
SK (1) SK281403B6 (fr)
SV (1) SV1993000080A (fr)
TW (1) TW372239B (fr)
UA (1) UA39158C2 (fr)
UY (1) UY23697A1 (fr)
YU (1) YU49411B (fr)
ZA (1) ZA939293B (fr)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476932A (en) * 1994-08-26 1995-12-19 Hoffmann-La Roche Inc. Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
EP0882734B1 (fr) * 1997-06-02 2009-08-26 F. Hoffmann-La Roche Ag Dérivés de 5'-déoxy-cytidine
NZ330360A (en) * 1997-06-02 1999-03-29 Hoffmann La Roche 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
US6005098A (en) * 1998-02-06 1999-12-21 Hoffmann-La Roche Inc. 5'deoxycytidine derivatives
WO2000018393A1 (fr) * 1998-09-25 2000-04-06 Warner-Lambert Company Chimiotherapie contre le cancer, dans laquelle de l'acetyldinaline combinee a de la gemcitabine, de la capecitabine ou du cisplatine sont utilises
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US20070122481A1 (en) * 1998-11-02 2007-05-31 Elan Corporation Plc Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer
HUP0300848A3 (en) * 2000-02-28 2005-03-29 Aventis Pharma Sa A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
AU2001246863A1 (en) * 2000-04-11 2001-10-23 Sayuri Yamada Curcumin compositions
KR100730768B1 (ko) * 2000-08-09 2007-06-21 코오롱생명과학 주식회사 5'-데옥시-ｎ-알킬옥시카르보닐-5-플루오로사이토신-5'-카르복실산 및 그 유도체와 이들의 제조방법
KR100631754B1 (ko) * 2000-08-09 2006-10-09 주식회사 코오롱 Ｎ-알킬옥시카르보닐-5-플루오로사이토신 유도체 및 그의제조방법
GB0113374D0 (en) * 2001-06-04 2001-07-25 Jerram Clare Washing line umbrella
EP1469847A1 (fr) 2002-01-14 2004-10-27 Novartis AG Combinaisons comprenant des epothilones et des antimetabolites
CA2477088A1 (fr) 2002-02-22 2003-10-02 New River Pharmaceuticals Inc. Systemes de distribution d'agents actifs et methodes de protection et d'administration d'agents actifs
MXPA05003431A (es) * 2002-11-15 2005-07-05 Warner Lambert Co Quimioterapia de combinacion.
WO2004105747A1 (fr) * 2003-05-20 2004-12-09 Aronex Pharmaceuticals, Inc Chimiotherapie combinee comprenant capecitabine et un complexe a base de platine liposomique
EP1689404B9 (fr) * 2003-11-13 2009-04-22 Pharma Mar, S.A.U. Combinaison du et-743 avec des pro-drugs du 5-fluorouracile pour le traitement du cancer
DE602004015331D1 (de) * 2003-12-22 2008-09-04 Hoffmann La Roche Verfahren für fluorcytidinderivate
PL1848414T3 (pl) 2005-02-03 2011-10-31 Wyeth Llc Sposób leczenia nowotworu opornego na gefitinib
AU2006228581A1 (en) * 2005-04-01 2006-10-05 F. Hoffmann-La Roche Ag Method for administration of capecitabine
KR20080035630A (ko) 2005-07-18 2008-04-23 바이파 사이언스 인코포레이티드 암의 치료
AU2006272343B2 (en) 2005-07-21 2012-09-13 Nuvo Research Ag Stabilized chlorite solutions in combination with fluoropyrimidines for cancer treatment.
EP1942937A1 (fr) 2005-11-04 2008-07-16 Wyeth Combinaisons antineoplasiques a base d'inhibiteur de mtop, d'herceptine et/ou de khi-272
DK2474545T3 (en) 2005-12-13 2017-01-23 Incyte Holdings Corp Heteroberl-substituted pyrrolo [2,3-b] pyridines and pyrrolo [2,3-b] pyrimidines as Janus kinase inhibitors
US20100160442A1 (en) * 2006-07-18 2010-06-24 Ossovskaya Valeria S Formulations for cancer treatment
US20080085310A1 (en) * 2006-10-06 2008-04-10 Maria Oksana Bachynsky Capecitabine rapidly disintegrating tablets
CN100425617C (zh) * 2006-10-31 2008-10-15 浙江海正药业股份有限公司 一种含氟嘧啶类化合物烷氧羰酰化的方法
ITMI20070435A1 (it) 2007-03-05 2008-09-06 Innovate Biotechnology Srl 2',3'-di-o-acil-5-fluoronucleosidi
JP2010524960A (ja) * 2007-04-20 2010-07-22 ドクター・レディーズ・ラボラトリーズ・リミテッド カペシタビンを調製するためのプロセス
WO2008145403A1 (fr) * 2007-06-01 2008-12-04 Synthon B.V. Procédés se rapportant à la fabrication de la capécitabine
GEP20125533B (en) 2007-06-13 2012-05-25 Incyte Corp Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentyl propanenitrile
US7842675B2 (en) * 2007-09-15 2010-11-30 Protia, Llc Deuterium-enriched capecitabine
US8741858B2 (en) * 2007-09-21 2014-06-03 Zhongxu Ren Oligomer-nucleoside phosphate conjugates
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
KR101013312B1 (ko) * 2007-11-19 2011-02-09 한미홀딩스 주식회사 카페시타빈의 제조방법 및 이에 사용되는 β-아노머가강화된 트리알킬카보네이트 화합물의 제조방법
AR064165A1 (es) 2007-12-06 2009-03-18 Richmond Sa Com Ind Y Financie Un procedimiento para la preparacion de capecitabina e intermediarios utilizables en dicho procedimiento
US20090209754A1 (en) * 2008-01-03 2009-08-20 Macdonald Peter Lindsay Process for the preparation of capecitabine
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
ES2609232T3 (es) 2008-06-17 2017-04-19 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
EP3175853B1 (fr) 2008-08-04 2023-11-01 Wyeth LLC Combinaisons antinéoplasiques contenant du neratinib et de la capécitabine
EP2370414A4 (fr) * 2008-12-02 2012-11-14 Reddys Lab Ltd Dr Préparation de capécitabine
US8603999B2 (en) 2008-12-05 2013-12-10 Commonwealth Scientific And Industrial Research Organisation Amphiphile prodrugs
FI3000467T3 (fi) 2009-04-06 2023-03-28 Wyeth Llc Rintasyöpähoitokuuri, jossa käytetään neratinibia
FR2945211A1 (fr) 2009-05-06 2010-11-12 Sanofi Aventis Combinaison antitumorale comprenant la cabazitaxel et la capecitabine
UA106078C2 (uk) 2009-05-22 2014-07-25 Інсайт Корпорейшн 3-[4-(7H-ПІРОЛО[2,3-d]ПІРИМІДИН-4-ІЛ)-1H-ПІРАЗОЛ-1-ІЛ]ОКТАН- АБО ГЕПТАННІТРИЛ ЯК JAK-ІНГІБІТОРИ
CN102858791A (zh) * 2009-07-23 2013-01-02 台湾神隆股份有限公司 制备氟胞苷衍生物的方法
WO2011067588A1 (fr) 2009-12-04 2011-06-09 Generics [Uk] Limited Esters sulfinyle cycliques de cytidine
WO2011104540A1 (fr) * 2010-02-24 2011-09-01 Generics [Uk] Limited Procédé en une étape pour la préparation de la capécitabine
KR102172742B1 (ko) 2010-03-10 2020-11-02 인사이트 홀딩스 코포레이션 Ｊａｋ１ 저해제로서의 피페리딘­４­일 아제티딘 유도체
EP3117709B1 (fr) 2010-03-12 2018-08-01 Genzyme Corporation Therapie combinee pour le traitement du cancer du sein
SI2574168T1 (sl) 2010-05-21 2016-07-29 Incyte Holdings Corporation Topična formulacija zaviralca jak
CN102260309B (zh) * 2010-05-24 2014-10-22 重庆福安药业(集团)股份有限公司 一种高纯度卡培他滨的制备方法
SG190839A1 (en) 2010-11-19 2013-07-31 Incyte Corp Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
CN102558262A (zh) * 2010-12-23 2012-07-11 天津泰普药品科技发展有限公司 一种高纯度卡培他滨的制备方法
MX344479B (es) 2011-06-20 2016-12-16 Incyte Holdings Corp Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de cinasa janus (jak).
CN102266303A (zh) * 2011-07-07 2011-12-07 程雪翔 一种卡培他滨药用组合物及其制备方法
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
CN102516338B (zh) * 2011-12-09 2014-04-02 海南锦瑞制药股份有限公司 一种卡培他滨化合物、其药物组合物及其制备方法
TWI560195B (en) * 2012-01-13 2016-12-01 Pharmaessentia Corp Novel synthesis of 5-deoxy-5'-fluorocytidine compounds
SI2919766T1 (sl) 2012-11-15 2021-11-30 Incyte Holdings Corporation Farmacevtske oblike ruksolitiniba s podaljšanim sproščanjem
BR122021015061B1 (pt) 2013-03-06 2022-10-18 Incyte Holdings Corporation Processos e intermediários para preparar um inibidor de jak
SG10201801069QA (en) 2013-08-07 2018-03-28 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
AU2014309017A1 (en) * 2013-08-20 2016-03-10 Incyte Corporation Survival benefit in patients with solid tumors with elevated C-reactive protein levels
EP2883959A1 (fr) 2013-12-13 2015-06-17 Plasmia Biotech, S.L. Production enzymatique d'analogues de nucléoside cytosinique
CN103897006A (zh) * 2013-12-18 2014-07-02 吉林修正药业新药开发有限公司 一种卡培他滨异构体的制备方法
WO2015191563A1 (fr) 2014-06-09 2015-12-17 Lipomedix Pharmaceuticals Ltd. Polychimiothérapie comprenant un promédicament liposomal de mitomycine c
CN104530164A (zh) * 2014-12-31 2015-04-22 辰欣药业股份有限公司 一种卡培他滨的合成工艺
KR20160117060A (ko) 2015-03-31 2016-10-10 이승주 유아용 탁자
CN105646625B (zh) * 2015-12-29 2019-06-11 江苏吴中医药集团有限公司 一种卡培他滨的制备方法
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
ES2914123T3 (es) 2017-01-09 2022-06-07 Shuttle Pharmaceuticals Inc Inhibidores selectivos de la histona desacetilasa para el tratamiento de una enfermedad humana
TR201702500A2 (tr) * 2017-02-20 2017-07-21 Anadolu Ueniversitesi Serani̇b-2?ni̇n akci̇ğer kanseri̇ ve meme kanseri̇ni̇n tedavi̇si̇nde kullanimi
US10435429B2 (en) 2017-10-03 2019-10-08 Nucorion Pharmaceuticals, Inc. 5-fluorouridine monophosphate cyclic triester compounds
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
EP3737376B1 (fr) 2018-01-09 2024-04-17 Shuttle Pharmaceuticals, Inc. Inhibiteurs sélectifs d'histone déacétylase pour le traitement de maladies humaines
WO2019139920A1 (fr) 2018-01-10 2019-07-18 Nucorion Pharmaceuticals, Inc. Composés de phosphore(n)amidatacétal et phosph(on)atalcétal
CN111801339A (zh) * 2018-01-19 2020-10-20 纽科利制药公司 5-氟尿嘧啶化合物
US11427550B2 (en) 2018-01-19 2022-08-30 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
TWI797242B (zh) 2018-01-30 2023-04-01 美商英塞特公司 製備ｊａｋ抑制劑之方法及中間物
CA3095487A1 (fr) 2018-03-30 2019-10-03 Incyte Corporation Traitement de l'hidradenite suppuree a l'aide d'inhibiteurs de jak
JP2022517352A (ja) 2019-01-11 2022-03-08 リポメディックス・ファーマシューティカルズ・リミテッド マイトマイシンｃのリポソーム化プロドラッグを含むリポソーム組成物および製造法
MX2022000573A (es) 2019-07-17 2022-02-10 Nucorion Pharmaceuticals Inc Compuestos ciclicos de desoxirribonucleotido.
JP2023523415A (ja) 2020-04-21 2023-06-05 リガンド・ファーマシューティカルズ・インコーポレイテッド ヌクレオチドプロドラッグ化合物
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2023177894A1 (fr) 2022-03-18 2023-09-21 Ideaya Biosciences, Inc. Polythérapie comprenant un inhibiteur de mat2a et un agent antimétabolite
EP4382093A1 (fr) 2022-12-05 2024-06-12 a Fine House S.A. Suspensions orales comprenant de la capécitabine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1135258A (fr) * 1979-06-15 1982-11-09 Richard D'souza Procede d'obtention de 5'-desoxy-5- fluorouridine
CA1264738A (fr) * 1984-12-04 1990-01-23 Eli Lilly And Company Traitement des tumeurs chez les mammiferes
CA1327358C (fr) * 1987-11-17 1994-03-01 Morio Fujiu Derives fluorocytidine

Also Published As

Publication number Publication date
HU211965A9 (en) 1996-01-29
BG61485B1 (bg) 1997-09-30
ES2086856T3 (es) 1996-07-01
LTIP1627A (en) 1994-07-15
BR9305089A (pt) 1994-07-05
NO300066B1 (no) 1997-04-01
LT3115B (en) 1994-12-27
SA93140409B1 (ar) 2004-07-24
SK281403B6 (sk) 2001-03-12
NO934671D0 (no) 1993-12-17
BG98304A (bg) 1994-01-03
DE69302360D1 (de) 1996-05-30
DE69302360T2 (de) 1996-10-31
RU2135511C1 (ru) 1999-08-27
CA2103324A1 (fr) 1994-06-19
SK144493A3 (en) 1994-10-05
LV10625A (lv) 1995-04-20
PL174100B1 (pl) 1998-06-30
CZ284788B6 (cs) 1999-03-17
SI9300648A (en) 1994-09-30
CN1035617C (zh) 1997-08-13
FI935616A (fi) 1994-06-19
IS4108A (is) 1994-06-19
HU9303525D0 (en) 1994-04-28
PH30168A (en) 1997-01-21
RU2458932C2 (ru) 2012-08-20
HK1005875A1 (en) 1999-01-29
NO934671L (no) 1994-06-20
EE03086B1 (et) 1998-04-15
EP0602454A1 (fr) 1994-06-22
HRP931430B1 (en) 1999-08-31
HUT65757A (en) 1994-07-28
HRP931430A2 (en) 1998-06-30
NZ250414A (en) 1995-12-21
GEP20074251B (en) 2007-12-10
GR3020286T3 (en) 1996-09-30
RO112619B1 (ro) 1997-11-28
US5472949A (en) 1995-12-05
JP2501297B2 (ja) 1996-05-29
YU77993A (sh) 1996-10-18
MY109282A (en) 1996-12-31
AU5069093A (en) 1994-06-30
CZ273193A3 (en) 1994-07-13
ATE137244T1 (de) 1996-05-15
SI9300648B (sl) 2000-06-30
ZA939293B (en) 1994-06-18
SV1993000080A (es) 1996-01-26
CN1094056A (zh) 1994-10-26
AU671491B2 (en) 1996-08-29
LV10625B (en) 1996-04-20
JPH06211891A (ja) 1994-08-02
KR940014428A (ko) 1994-07-18
KR100347218B1 (ko) 2003-01-24
UY23697A1 (es) 1994-06-08
PL301541A1 (en) 1994-06-27
FI935616A0 (fi) 1993-12-14
CA2103324C (fr) 1997-12-23
RU2493162C1 (ru) 2013-09-20
HU218291B (en) 2000-07-28
TW372239B (en) 1999-10-21
YU49411B (sh) 2006-01-16
EP0602454B1 (fr) 1996-04-24
FI112365B (fi) 2003-11-28
IL108000A0 (en) 1994-04-12
UA39158C2 (uk) 2001-06-15

Similar Documents

Publication Publication Date Title
DK0602454T3 (da) N-oxycarbonylsubstituerede 5-deoxy-5-fluorcytidiner
RU93056196A (ru) N-карбонилзамещенные 5'-дезокси-5-фторцитидина
GR3020150T3 (en) Benzylidene azolyl methyl cycloalkane and its use as a fungicide
DE68905627D1 (de) Hydrophile sauerstoffdurchlaessige polymere.
HU9401976D0 (en) N,n'-substituted imidocarbonimidic diamides, pharmaceutical compositions containing them and use of these compounds aganst infection
CA2065978A1 (fr) Composes organosilicies renfermant des groupes (meth)acryloxy; preparation et utilisation
EP0401715A3 (fr) Composés aminocétoniques